Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352429 · ClinicalTrials.gov registry record
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
A clinical trial of Prostate Adenocarcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 303
- Enrollment target
- 2
- Study locations
NCT01352429 is a study of Prostate Adenocarcinoma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 303 participants, above the 215-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (41% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT01352429, a study of Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 303 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or Intensity Modulated Radiation Therapy (IMRT). The investigators propose to employ a hypofractionated strategy with our image guided treatment to further improve cancer control and decrease toxicity.
Conditions Studied
Interventions
- RADIATION IMRT
- RADIATION Proton Therapy
Study Locations (2)
Maryland
- Walter Reed National Military Medical Center - Bethesda
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2009-08 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01352429
The ClinicalTrials.gov registry entry for NCT01352429 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 215-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (41% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which IMRT is the first listed.
NCT01352429 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01352429 about?
NCT01352429 is a clinical study titled "Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer". This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or Intensity Modulated Radiation Therapy (IMRT)...
What is the current status of trial NCT01352429?
This trial is currently active not recruiting. The enrollment target is 303 participants. The study started on 2009-08. Estimated completion is 2026-12.
What conditions does trial NCT01352429 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT01352429?
The interventions under investigation include: IMRT (RADIATION), Proton Therapy (RADIATION).
Who is sponsoring clinical trial NCT01352429?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01352429 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RECRUITING · Early Phase 1
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.